Clinical Trial Update: A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating adalimumab for active pyoderma gangrenosum in Japan has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pyoderma Gangrenosum

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: AbbVie | Conditions: Pyoderma Gangrenosum | Phase 3 | Status: COMPLETED